Author:
Bock B V,Edelstein P H,Meyer R D
Abstract
Eighty patients were treated with either amikacin or netilmicin in a prospective randomized study of serious gram-negative bacillary infections, including 11 due to gentamicin-resistant pathogens. Thirty-six treated with netilmicin and 35 treated with amikacin were evaluable for efficacy or toxicity, or both. The overall groups differed significantly only in age. There were no significant differences in efficacy of the two drugs. There were no statistically significant differences at the 95% level between the netilmicin group and the amikacin group with respect to nephrotoxic reactions (38 versus 28%, respectively) or ototoxic reactions (9 versus 25%, respectively). Further comparative trials of netilmicin and other aminoglycosides appear warranted before it is widely used.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference30 articles.
1. Antibiotic susceptibility testing by a standardized single disc method;Bauer A. W.;Am. J. Clin. Pathol.,1966
2. Clinical efficacy of netilmicin in the treatment ofgram-negative infections;Buckwold F. J.;Can. Med. Assoc. J.,1979
3. Prediction of creatinine clearance from serum creatinine;Crockcroft D. W.;Nephron,1976
4. In vitro studies with netilmicin compared with amikacin, gentamicin and tobramycin;Dhawan V.;Antimicrob. Agents Chemother.,1977
5. Netilmicin therapy of serious gram-negative bacillary infections;Edelstein P. H.;J. Antimicrob. Chemother.,1978
Cited by
52 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献